Thermo Fisher Scientific Completes Large-Scale Proteomic Analysis for Landmark Parkinson’s Disease Study
Thermo Fisher Scientific Inc., a global leader in scientific research services and technologies, has announced the completion of a large-scale proteomic analysis involving approximately 5,500 research samples from The Michael J. Fox Foundation’s (MJFF) Parkinson’s Precision Medicine Initiative (PPMI). The project represents an important expansion of the molecular data available to researchers studying Parkinson’s disease and is expected to provide new opportunities to investigate disease biology, identify potential biomarkers and advance precision medicine approaches.
The newly generated proteomic data have been added to the PPMI data repository, where they are accessible to the global research community. By making the information broadly available, the collaboration between Thermo Fisher and MJFF aims to enable scientists around the world to explore protein-level changes associated with Parkinson’s disease and integrate those findings with other types of biological and clinical information.
The analysis was conducted using Olink Explore HT, a high-throughput proteomics platform from Olink, which is part of Thermo Fisher Scientific. The technology uses a Proximity Extension Assay (PEA)-based approach to measure proteins at scale, creating detailed molecular profiles that researchers can use to explore biological processes involved in disease.
Expanding the Molecular Understanding of Parkinson’s Disease
Parkinson’s disease is one of the most prevalent neurodegenerative disorders worldwide, with an estimated 10 million people living with the condition globally. The number of people affected is expected to increase as populations age.
Despite decades of research, Parkinson’s disease remains challenging to diagnose and monitor. Clinical assessment continues to play a central role in diagnosis, but symptoms can vary significantly among patients. Individuals may experience different combinations and rates of motor and non-motor symptoms, making it increasingly clear that Parkinson’s disease is not a single, biologically uniform disorder.
Researchers are therefore placing greater emphasis on understanding the molecular mechanisms underlying the disease. Rather than relying solely on clinical characteristics, the field is moving toward identifying biological signatures that can reveal different disease subtypes, predict progression and potentially guide treatment decisions.
Proteomics is an important component of this transition.
While genomic research examines DNA and genetic variation, proteomic analysis focuses on proteins, which are directly involved in many of the biological processes that determine how cells function. Changes in protein levels, activity and interactions can provide information about disease mechanisms that may not be apparent from genetic data alone.
The newly generated PPMI dataset therefore provides researchers with another layer of biological information that can be combined with the study’s extensive clinical and molecular resources.
Olink Technology Supports High-Throughput Proteomic Research
Olink Explore HT is designed to enable high-throughput measurement of proteins using affinity-based proteomic technology. Its PEA methodology allows researchers to analyze numerous protein targets across large numbers of samples.
For Parkinson’s disease research, this capability can be particularly valuable because the disease involves numerous biological pathways. Researchers can use proteomic information to investigate processes associated with inflammation, neuronal stress, lysosomal function and other mechanisms believed to contribute to neurodegeneration.
The ability to analyze thousands of samples also allows scientists to look beyond individual cases and investigate patterns across patient populations.
Large-scale datasets can potentially help researchers identify groups of patients who share similar molecular characteristics. These biological subgroups may eventually help explain why some patients progress more rapidly than others, why individuals experience different symptoms and why certain treatments may work better for particular populations.
The proteomic data can also be compared with longitudinal clinical information to investigate how molecular changes evolve over time.
PPMI Provides a Valuable Foundation for Precision Medicine
The Parkinson’s Precision Medicine Initiative was launched by The Michael J. Fox Foundation in 2010. The initiative was recently renamed to emphasize the growing importance of defining Parkinson’s disease according to its underlying biology rather than clinical symptoms alone.
PPMI has developed into a major international research effort, collecting extensive clinical, genetic, imaging and other molecular data from participants. Its open-access approach allows scientists around the world to access the information and conduct independent research.
According to MJFF, PPMI data have been downloaded more than 50 million times, demonstrating the scale of interest from the global scientific community.
Adding large-scale proteomic information to this resource further increases the potential value of the dataset.
Researchers can now potentially combine protein measurements with other forms of PPMI data to investigate relationships between molecular changes and clinical outcomes. For example, scientists may be able to examine whether particular protein signatures are associated with disease onset, progression, specific symptoms or other biological characteristics.
Such analyses could generate hypotheses for future studies and help identify biomarkers that require further validation.
Potential Role in Biomarker Discovery
One of the major challenges in Parkinson’s disease research is developing reliable biomarkers.
A useful biomarker could potentially help researchers detect disease earlier, distinguish biological subtypes, monitor progression or evaluate whether a treatment is having its intended effect.
Currently, many aspects of Parkinson’s disease assessment depend on clinical observation and symptom-based measurements. While these approaches remain important, they may not fully capture the underlying biological changes taking place in the brain and throughout the body.
Proteomic analysis could help fill some of these gaps by providing measurable molecular signals.
By examining thousands of proteins simultaneously, scientists can search for patterns that differentiate individuals with Parkinson’s disease from healthy participants or distinguish different disease trajectories. Candidate biomarkers discovered through this type of analysis would then require additional testing and validation before they could potentially be used in clinical practice.
The availability of the new PPMI proteomic dataset gives researchers an opportunity to conduct this discovery and validation work using a deeply characterized population.
Combining Proteomics With Multi-Omics Data
The greatest potential of the project may come from integrating proteomic information with other biological datasets.
Modern precision medicine increasingly relies on multi-omics approaches, combining information from genomics, transcriptomics, proteomics, metabolomics and other molecular disciplines. Each layer provides a different perspective on biology.
Genomic data can identify inherited or acquired genetic variation, while proteomic data can provide information about the functional consequences of biological processes. When these datasets are analyzed alongside clinical assessments, imaging and longitudinal measurements, researchers may gain a more comprehensive understanding of Parkinson’s disease.
This integrated approach could also support the development of more sophisticated disease models and help identify molecular pathways that warrant further investigation.
The availability of the data through PPMI’s repository means researchers do not have to be part of the original Thermo Fisher or MJFF project to explore the findings. Instead, the resource can serve as a foundation for independent research efforts around the world.
MJFF Highlights the Importance of Biological Research
Samantha Hutten, PhD, Principal Biomarker Scientist, Translational Research at The Michael J. Fox Foundation, emphasized the complexity of Parkinson’s disease and the importance of studying multiple layers of biology.
According to Hutten, expanding proteomic analysis within PPMI creates additional opportunities to identify biomarkers and investigate biological pathways that could eventually contribute to earlier diagnosis, improved disease monitoring and more targeted treatment strategies.
The comments highlight a broader shift occurring across neurodegenerative disease research. Scientists increasingly recognize that understanding disease requires more than identifying a single genetic factor or clinical symptom. Instead, research must consider the complex interactions between biological systems and how those interactions change throughout disease progression.
Thermo Fisher Focuses on Translating Discovery Into Validation
For Thermo Fisher, the completion of the analysis represents another step toward expanding the use of proteomics in biomedical research.
Yan Zhang, president of proteomic sciences at Thermo Fisher, noted that discovering potential molecular signals is only the beginning. The next challenge is determining which signals can be consistently reproduced, demonstrate clinical relevance and ultimately contribute to precision medicine.
Making the PPMI proteomic data available to researchers is intended to accelerate that process.
Scientists can use the dataset to test hypotheses, compare findings across cohorts and identify molecular signals that may warrant additional research. Over time, repeated validation could help determine which protein signatures have the greatest potential for clinical translation.
A Growing Resource for Parkinson’s Research
The completion of proteomic analysis across approximately 5,500 PPMI research samples significantly expands the molecular depth of one of the world’s major Parkinson’s disease research resources.
As researchers increasingly embrace precision medicine, large datasets that combine clinical, genetic, imaging and molecular information are becoming essential. Proteomics adds another important dimension by providing insights into proteins and biological pathways directly involved in cellular function.
The newly available data could support research into Parkinson’s disease heterogeneity, disease progression, biomarker discovery and therapeutic development. Although additional research and validation will be necessary before any individual biomarker or molecular signature can be translated into clinical use, the resource provides scientists with an important foundation for that work.
By combining PPMI’s extensive longitudinal research infrastructure with Thermo Fisher’s high-throughput proteomic capabilities, the initiative demonstrates how large-scale collaboration can expand the biological understanding of complex neurodegenerative disorders.
Ultimately, the goal is to move Parkinson’s disease research toward a future in which patients can be more precisely characterized according to their underlying biology, disease progression can be monitored using objective molecular measures and therapies can be developed or selected according to the biological characteristics of individual patients.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.
Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.